In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $3.85.
According to TipRanks, LeBoyer is an analyst with an average return of -6.6% and a 28.29% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as GeoVax Labs, PDS Biotechnology, and Unicycive Therapeutics.
PDS Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $16.33, implying a 324.16% upside from current levels. In a report released today, B.Riley Financial also reiterated a Buy rating on the stock with a $11.00 price target.
PDSB market cap is currently $119.8M and has a P/E ratio of -2.78.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology (PDSB) Company Description:
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- Options Volatility and Implied Earnings Moves Today, March 27, 2024
- PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
- PDS Biotechnology reports 2023 EPS ($1.39), consensus ($1.46)
- PDS Biotechnology to prioritize triple combination in place of VERSATILE-003
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
